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Pneumocystis jiroveci pneumonia (PCP) is an important 
cause of hospitalisation and death in HIV-infected children 
in Africa.1-4 Untreated PCP is fatal in 100% of cases.5 
Recommended treatment is intravenous trimethoprim-
sulphamethoxazole (TMP-SMZ) followed by oral therapy 
once clinical improvement occurs to complete 21 days of 
therapy.5  Intravenous therapy should be used initially as serum 
levels of 5 - 10 µg/ml of TMP are recommended for effective 
treatment of PCP. 6,7 However, establishment of intravenous 
access requires specific skill, may be especially difficult in very 
young or malnourished children and is a painful procedure.  
Furthermore, as the response to therapy may be slow (4 - 8 
days before clinical improvement occurs) repeated insertion of 
intravenous lines may be required.5  In addition, this procedure 
poses a risk of transmitting HIV to health care workers via 
needlestick injury.  Administration of intravenous TMP-SMZ 
is also more costly, difficult and time-consuming than oral 
medication and may result in fluid overload.8 Because of these 
difficulties, oral TMP-SMZ is often used for treatment of PCP 
in South Africa and other developing countries despite lack of 
data on the efficacy of such therapy.     
   Poor response to treatment with TMP-SMZ has been 
described in a few patients with very low peak levels of 
TMP.6 In addition, low serum TMP concentrations have 
been associated with failure to respond to TMP-SMZ during 
the first 3 days of treatment.7 It is therefore important to 
attain therapeutic serum levels of TMP for treatment of 
PCP. Pharmacokinetic studies in non-HIV-infected patients 
suggest that serum TMP concentrations of 5 - 10 µg/ml are not 
attainable with standard oral doses of TMP-SMZ.8 In HIV-
infected children, altered absorption and metabolism of TMP-
SMZ as a result of gastrointestinal, hepatic or renal disease 
may further reduce serum TMP concentrations. However, it is 
possible that therapeutic TMP levels may be attained with oral 
medication if increased dosages are used. The aim of this study 
was to determine whether therapeutic TMP concentrations 
of 5 - 10 µg/ml could be attained using oral therapy in the 
treatment of PCP.    
Methods 
A prospective dose-escalation study was undertaken to 
investigate serum TMP levels after administration of different 
oral dosages of TMP-SMZ to HIV-infected children. The study 
was approved by the Research and Ethics Committee of the 
University of Cape Town. Written, informed consent was 
obtained from a parent or guardian.
   Fifteen stable HIV-infected children who were taking 
TMP-SMZ for PCP prophylaxis and who were attending the 
School of Child and Adolescent Health, Red Cross War Memorial Children’s 
Hospital, Cape Town 
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Background. Effective treatment of Pneumocystis jiroveci 
pneumonia (PCP) requires therapeutic serum concentrations of 
5 - 10 µg/ml trimethoprim (TMP); consequently intravenous 
trimethoprim-sulphamethoxazole (TMP-SMZ) is recommended 
therapy. However, oral therapy is desirable as the intravenous 
route is costly, time-consuming, more difficult to administer 
and carries a risk of needlestick injury.  
Objective. To investigate whether therapeutic TMP levels for 
treatment of PCP can be attained with oral therapy in HIV-
infected children.
Methods. A prospective dose-escalation study was undertaken 
of serum TMP levels attained following oral doses of TMP 
of 5  mg/kg, 10 mg/kg or 20 mg/kg in stable HIV-infected 
children. Children who received a 20 mg/kg dose were 
randomised to get a second dose (5 or 10 mg/kg TMP) at 
6 hours. TMP levels were measured at baseline, peak (3 
hours), and trough (6 hours) using liquid chromatography. 
An additional TMP level was taken at 9 hours in those who 
received a second TMP dose. 
Results. Median (25th - 75th percentile) peak serum TMP levels 
following a 5 mg/kg, 10 mg/kg or 20 mg/kg oral loading 
dose were 0.93 (0.5 - 1.5) µg/ml, 1.94 (1.4 - 2.2) µg/ml and 7.68 
(6.1- 7.8) µg/ml respectively. Peak TMP levels at 9 hours after a 
second TMP dose of 5 or 10 mg/kg were 6.98 (3.4 - 8.8) µg/ml 
and 9.25 (8.2 - 10.3) µg/ml respectively.  
Conclusion. Therapeutic concentrations of TMP for treatment of 
P. jiroveci can be attained with an oral loading dose of 20 mg/kg 
and sustained with a second dose at 6 hours of either 5 mg or 10 
mg/kg in stable HIV-infected children. 
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outpatient infectious diseases clinic at Red Cross Children’s 
Hospital were studied. Exclusion criteria were inability 
to take oral medicine, ongoing chronic diarrhoea, known 
hypersensitivity to TMP-SMZ, severe anaemia (haemoglobin 
less than 8 g/dl), neutropenia (neutrophil count less than           
1 000/µl) or thrombocytopenia (platelet count less than 80  000/
µl), renal failure or any acute illness within the preceding 2 
weeks.    
   Children were studied 48 - 72 hours after their last dose of 
TMP-SMZ prophylaxis.   
   An oral loading dose of 5 mg/kg, 10 mg/kg or 20 mg/kg 
TMP was administered to children using a suspension (40 mg 
TMP and 200 mg SMZ per 5 ml of Cozole suspension, Be-Tabs 
Pharmaceuticals, Roodepoort, South Africa).  Thereafter those 
who received a 20 mg/kg dose of TMP were randomised using 
a computer-generated list to receive a second dose of either 5 
or 10 mg/kg TMP 6 hours after the loading dose.  Blood was 
drawn at baseline and at 3 and 6 hours after the oral loading 
dose for TMP levels using an indwelling catheter. Where 
children received a second TMP dose, an additional blood 
specimen was taken at 9 hours.
   Measurement of serum TMP levels was based on the method 
of Laizure et al.9 using high-pressure liquid chromatography. 
The technician performing TMP levels was blinded as to 
the dose of drug that had been administered. The drug was 
extracted from 200 µl of serum by solid-phase extraction. 
Buffered samples were eluted through a preconditioned solid-
phase column with methanol and dried down at 37oC. Dried 
samples were reconstituted in mobile phase (35% acetonitrile: 
65% heptane sulfonic acid, pH 3.0) and quantitated using a 
Luna 3 µm reverse-phase column (Phenomenex, Torrance, 
Calif.). Absorbance was monitored at 240 nm.  
Results  
Of the 15 children (median (25th - 75th percentile) age 23.5      
(11 - 40) months) enrolled, 4 patients received a loading dose of 
5 mg/kg TMP, 6 received a loading dose of 10 mg/kg TMP and 
5 received a loading dose of 20 mg/kg TMP. The median weight 
of the children was 10.7 (8.5 - 14.1) kg.     
   Baseline serum TMP levels were undetectable in all children. 
The median (25th - 75th percentile) serum TMP levels (µg/
ml) obtained with a 5 mg/kg loading dose at 3 and 6 hours 
were 0.93 µg/ml (0.5 - 1.5) µg/ml and 0.77 (0.3 - 2.0) µg/ml 
respectively.  Levels obtained with a 10 mg/kg loading dose 
were also subtherapeutic at 3 hours (1.94 (1.4 - 2.2) µg/ml) 
and 6 hours (1.3 (1.2 - 2.3) µg/ml). However, therapeutic TMP 
concentrations were obtained with a 20 mg/kg loading dose 
at both these time intervals (7.68 (6.1 - 7.8) µg/ml and 6.74 
(6.4  - 6.8) µg/ml respectively) (Fig. 1). In children who had 
received a 20 mg/kg loading dose, serum TMP levels at 9 hours 
after a second dose of either 5 or 10 mg/kg TMP were 6.98 
(3.4 - 8.8) µg/ml and 9.25 (8.2 - 10.3) µg/ml respectively and 
were therefore maintained within the therapeutic range (Fig.1).  
TMP-SMZ was well tolerated by all children and no adverse 
events were noted.  
Discussion
In this study, therapeutic serum TMP levels for treatment of 
PCP were attained with an oral loading dose of 20 mg/kg TMP 
and sustained with a second dose of either 5 mg or 10 mg/kg 
TMP given 6 hours later in a group of stable HIV-infected 
children.  However, subtherapeutic levels occurred in children 
given a lower loading dose.  The importance of therapeutic 
serum TMP levels has been suggested by studies6,7 in which 
peak serum TMP levels of less than 5 µg/ml were associated 
with a poor response to PCP therapy. Low peak TMP levels 
have been associated with failure of TMP-SMZ therapy in adult 
non-HIV-infected patients in whom histological confirmation 
of PCP was obtained at autopsy.6 Hughes et al.7 reported that 
children who failed to respond to TMP-SMZ within the first 
3 days of therapy had lower serum TMP concentrations than 
those who demonstrated a rapid clinical response; differences 
in TMP peaks were particularly evident during the first day 
of therapy. Such data underscore the importance of rapidly 
establishing a therapeutic TMP level in children with PCP, 
hence the use of a loading dose.  In our study an oral loading 
dose 4 times the conventionally administered dose was 
necessary to establish a therapeutic TMP concentration.       
   Although intravenous TMP-SMZ has been recommended for 
treatment of PCP, this study suggests that adequate TMP levels 
can be attained with high-dose oral therapy.  This is consistent 
with pharmacokinetic studies of adults that have reported oral 
TMP-SMZ to be well absorbed.10,11 However, a pharmacokinetic 
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Fig. 1. Serum TMP concentrations in HIV-infected children following 
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study of HIV-uninfected patients8 found that significantly 
higher mean increments of serum TMP levels were obtained 
following intravenous compared with oral administration. 
Moreover, our study involved stable HIV-infected children; 
the results may therefore not be generalisable to those who 
are acutely ill and who may have impaired absorption or 
metabolism of drugs. In addition, the children in the current 
study were older than those in whom PCP usually occurs, 
who are commonly infants aged 3 - 6 months.1-5 However, 
a pharmacokinetic study of HIV-uninfected patients8 found 
similar peak TMP concentrations in all ages. Further study is 
warranted on the efficacy and tolerability of oral TMP-SMZ 
in HIV-infected children with acute pneumonia in the doses 
shown in this study to achieve therapeutic levels before high-
dose oral treatment can be routinely recommended as first-line 
therapy. 
   In the absence of data on ill children, intravenous TMP-
SMZ therapy should preferably be used in very sick children, 
but where this is not feasible, oral therapy may be used.  
Increasingly, oral antibiotic therapy has been reported to 
be as effective as intravenous treatment for ill children, as 
demonstrated by a study in which oral amoxicillin and 
intravenous ampicillin were found to be equally effective in 
treating children with World Health Organization-defined 
severe pneumonia.12 TMP-SMZ is well absorbed orally.  
Nevertheless, before oral TMP-SMZ therapy can be routinely 
recommended for very sick children with suspected PCP, 
an optimal dosage needs to be established in this patient 
population. Such a study could only be done where subjects 
tolerate oral therapy, where there is close monitoring of TMP 
levels with the capacity to adjust the dose, and where careful 
monitoring of clinical response and adverse events is feasible. 
Although no adverse events occurred in our patients, adverse 
events including nausea, vomiting, diarrhoea and skin rashes 
have been reported frequently; bone marrow depression has 
rarely occurred. With prolonged therapy and higher doses 
careful monitoring for adverse events is warranted, including 
measurement of a full blood count.
   Establishment of an effective oral TMP-SMZ regimen for 
PCP is important for the treatment of HIV-infected children, 
particularly in countries with limited resources.  PCP has been 
reported to occur frequently as an AIDS-indicator disease 
among HIV-infected infants in Malawi and South Africa in 
association with a high mortality.2-6 As a result of the HIV 
pandemic in sub-Saharan Africa, increasing numbers of 
HIV-infected children may develop PCP, necessitating the 
development of effective, affordable management strategies.13 
Use of an effective oral TMP-SMZ regimen could provide a 
cost-effective, available alternative to intravenous therapy. 
In addition, use of an effective oral TMP-SMZ regimen may 
provide a safer alternative than intravenous therapy as the 
latter must be diluted in a large volume thus increasing the risk 
of fluid overload especially in young HIV-infected infants who 
may also have an HIV-associated cardiomyopathy.14
   Finally, measurement of TMP levels may prove useful 
for therapeutic monitoring of children who are treated for 
suspected or proven PCP. By adjusting the TMP-SMZ dose to 
maintain TMP levels at 5 - 8 µg/ml, toxicity was decreased 
while efficacy was maintained in HIV-infected adults with 
PCP.15 Monitoring of serum TMP concentrations may be one 
way of adjusting dosage to ensure that drug concentrations 
remain within the therapeutic range to provide optimal therapy 
for PCP.      
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